Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak; Pramote Euasobhon; Suthanee Cenpakdee; Suratsawadee Wangnamthip; Pranee Rushatamukayanunt

doi:10.12659/MSM.945612

19 September 2024 : Clinical Research

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak^1ABCDEF, Pramote Euasobhon^1ABCDEFG*, Suthanee Cenpakdee^1ABEF, Suratsawadee Wangnamthip^1ABDE, Pranee Rushatamukayanunt^1ABDE

DOI: 10.12659/MSM.945612

Med Sci Monit 2024; 30:e945612

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Average numeric rating scale pain, 3 negative emotional states of DASS-21, and EQ-5D-5L of before and after oxcarbazepine treatment. Data are presented as median and interquartile ranges. Statistical significance of P<0.05 is represented as *. This illustrates that pain scores and stress levels decreased significantly, and the quality of life scores improved significantly. Figure created using Microsoft Word (Version 2019, Microsoft Corporation).

Back to the Article

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Your Privacy